Physician profile
Raja G Devanathan
NPI 1871587220
$192,639.76
in general payments reported to CMS, 2019-2025
37 companies · $12K in 2025
The $12K reported for 2025 was more than what 93% of Pulmonary Disease providers received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $95K · 2020: $12K · 2021: $28K · 2022: $18K · 2023: $13K · 2024: $14K · 2025: $12K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $35K · Food and Beverage: $2,910 · Travel and Lodging: $367 · Education: $241.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $35,470.00 |
| Food and Beverage | $2,910.19 |
| Travel and Lodging | $366.70 |
| Education | $240.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $124,255.72 | 2019-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Astrazeneca Pharmaceuticals LP | $41,006.34 | 2019-2025 | Tezspire, Fasenra, Airsupra |
| Genentech USA, INC. | $15,314.74 | 2019-2024 | Xolair |
| Sunovion Pharmaceuticals INC. | $4,320.38 | 2019 | |
| Novartis Pharmaceuticals Corporation | $3,605.38 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,066.03 | 2020-2023 | Ofev |
| Inspire Medical Systems, INC. | $447.36 | 2023-2025 | Inspire |
| Janssen Pharmaceuticals, INC | $393.97 | 2019-2022 | |
| Actelion Pharmaceuticals US, INC. | $332.32 | 2021-2025 | Opsumit, Uptravi, Opsynvi |
| Ethicon INC. | $315.75 | 2022-2023 | Monarch Platform |
| Amgen INC. | $182.86 | 2022-2025 | Tezspire |
| Sanofi-Aventis U.S. LLC | $161.94 | 2024-2025 | |
| Insmed, INC. | $149.60 | 2019-2025 | Brinsupri, Arikayce |
| Regeneron Healthcare Solutions, INC. | $147.31 | 2023-2025 | Libtayo, Dupixent |
| Intuitive Surgical, INC. | $127.28 | 2025 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $126.85 | 2023-2025 | Glassia |
| Jazz Pharmaceuticals INC. | $106.71 | 2021 | |
| United Therapeutics Corporation | $99.62 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $99.06 | 2019 | |
| Genzyme Corporation | $96.57 | 2025 | |
| Mylan Specialty L.P. | $56.23 | 2023 | Yupelri |
| Philips North America LLC | $37.39 | 2025 | Patient Interface Software, Amara Cushions |
| Csl Behring | $24.92 | 2025 | Hizentra |
| Lilly USA, LLC | $22.96 | 2025 | Zepbound |
| Horizon Therapeutics Plc | $22.51 | 2019 | |
| Pulmonx Corporation | $17.72 | 2023 | Zephyr Delivery Catheter, Pulmonx Chartis Tablet Console, Chartis Catheter |
| Abbvie INC. | $17.37 | 2025 | |
| Ani Pharmaceuticals, INC. | $15.08 | 2025 | Purified Cortrophin Gel |
| Allergan, INC. | $14.62 | 2020 | |
| Fisher & Paykel Healthcare INC | $14.21 | 2024 | Fisher & Paykel Healthcare |
| Inogen, INC. | $14.03 | 2025 | |
| Electromed, INC. | $13.82 | 2025 | Smartvest |
| Pfizer INC. | $13.11 | 2021 |
4 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Raja Devanathan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.